Clinical Trials Logo

Clinical Trial Summary

Cerebral small vessel disease is a common cause of cognitive impairment. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion and increase cerebral blood flow. Patients with cognitive impairment, preserved basic activities of daily living, and brain computed tomography (CT) or magnetic resonance imaging (MRI) evidence of confluent white matter hyperintensities or multiple brain infarcts will be randomized to either RIC performed once a day on one arm, or twice per day on one arm, for 30 days, to test tolerability and effects on MRI markers of blood flow.


Clinical Trial Description

Cerebral small vessel disease (cSVD) accounts for 20-25% of all strokes and is the most common cause of vascular cognitive impairment (VCI) as well as a major contributor to mixed dementia, potentially interacting with Alzheimer's disease. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion. This is a prospective, open-label randomized controlled clinical trial with blinded endpoint assessment (PROBE). Participants that complete a 14-day run-in period will be randomized to 30 days of either: a) RIC performed once per day on one arm, or b) RIC performed twice per day on one arm. Each RIC session will consist of 4 cycles of unilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes, administered by modified blood pressure monitor (under an Investigational Trail Authorization from Health Canada). The primary outcome is tolerability, defined as the proportion in each trial arm that complete 80% or more of the assigned RIC sessions. Secondary outcomes will include pain scores, cognition, and MRI markers of cerebral blood flow and white matter integrity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04109963
Study type Interventional
Source University of Calgary
Contact Eric E Smith, MD
Phone 1-403-944-1594
Email eesmith@ucalgary.ca
Status Recruiting
Phase Phase 2
Start date September 26, 2019
Completion date March 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Completed NCT01761227 - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Phase 2
Active, not recruiting NCT01208675 - The Swedish BioFINDER Study
Completed NCT00165763 - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Phase 4
Completed NCT00621647 - Seroquel- Agitation Associated With Dementia Phase 3
Recruiting NCT04095962 - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia N/A
Recruiting NCT03275363 - The University of Hong Kong Neurocognitive Disorder Cohort N/A
Active, not recruiting NCT03804229 - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Phase 3
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Completed NCT02453932 - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Phase 3
Completed NCT00947531 - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Phase 4
Not yet recruiting NCT03702543 - Managing Vascular Dementia Risk Factors With SymTrend Phase 1
Enrolling by invitation NCT02147652 - Personalized Music Therapy and Agitation in Dementia N/A
Recruiting NCT04114994 - Longitudinal Cognitive Assessment by BoCA
Recruiting NCT06034509 - Cognitive and Vascular Functioning Following TBI
Recruiting NCT05921266 - Urolithin A Supplementation in Middle-aged Adults With Obesity N/A
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A
Not yet recruiting NCT01466543 - Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Phase 2
Completed NCT01345110 - A Longitudinal Multidimensional Population Study on Brain Aging N/A